164.56 USD
+6.44 (+4.07%)
164.36 USD
-0.2 (-0.12%)
We assign a fundamental rating of 5 out of 10 to ICLR. ICLR was compared to 58 industry peers in the Life Sciences Tools & Services industry. ICLR has only an average score on both its financial health and profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on ICLR. These ratings would make ICLR suitable for value investing!
1. Profitability
1.1 Basic Checks
ICLR had positive earnings in the past year.
ICLR had a positive operating cash flow in the past year.
In the past 5 years ICLR has always been profitable.
In the past 5 years ICLR always reported a positive cash flow from operatings.
1.2 Ratios
ICLR has a better Return On Assets (3.63%) than 75.86% of its industry peers.
The Return On Equity of ICLR (6.42%) is better than 75.86% of its industry peers.
ICLR has a Return On Invested Capital of 6.74%. This is in the better half of the industry: ICLR outperforms 75.86% of its industry peers.
ICLR had an Average Return On Invested Capital over the past 3 years of 5.80%. This is significantly below the industry average of 13.56%.
The 3 year average ROIC (5.80%) for ICLR is below the current ROIC(6.74%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROIC | 6.74% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
1.3 Margins
Looking at the Profit Margin, with a value of 7.40%, ICLR is in the better half of the industry, outperforming 75.86% of the companies in the same industry.
ICLR's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 13.99%, ICLR is doing good in the industry, outperforming 75.86% of the companies in the same industry.
In the last couple of years the Operating Margin of ICLR has remained more or less at the same level.
With a Gross Margin value of 28.15%, ICLR is not doing good in the industry: 74.14% of the companies in the same industry are doing better.
ICLR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% |
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICLR is destroying value.
Compared to 1 year ago, ICLR has less shares outstanding
Compared to 5 years ago, ICLR has more shares outstanding
Compared to 1 year ago, ICLR has an improved debt to assets ratio.
2.2 Solvency
ICLR has an Altman-Z score of 2.00. This is not the best score and indicates that ICLR is in the grey zone with still only limited risk for bankruptcy at the moment.
ICLR's Altman-Z score of 2.00 is in line compared to the rest of the industry. ICLR outperforms 48.28% of its industry peers.
ICLR has a debt to FCF ratio of 3.53. This is a good value and a sign of high solvency as ICLR would need 3.53 years to pay back of all of its debts.
The Debt to FCF ratio of ICLR (3.53) is better than 79.31% of its industry peers.
ICLR has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
ICLR's Debt to Equity ratio of 0.31 is in line compared to the rest of the industry. ICLR outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Altman-Z | 2 |
ROIC/WACC0.8
WACC8.46%
2.3 Liquidity
ICLR has a Current Ratio of 1.06. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.06, ICLR is not doing good in the industry: 86.21% of the companies in the same industry are doing better.
A Quick Ratio of 1.06 indicates that ICLR should not have too much problems paying its short term obligations.
ICLR's Quick ratio of 1.06 is on the low side compared to the rest of the industry. ICLR is outperformed by 77.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
ICLR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.99%.
The Earnings Per Share has been growing by 15.23% on average over the past years. This is quite good.
The Revenue has decreased by -2.46% in the past year.
ICLR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.17% yearly.
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
3.2 Future
ICLR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.61% yearly.
The Revenue is expected to grow by 2.38% on average over the next years.
EPS Next Y-4.67%
EPS Next 2Y-0.67%
EPS Next 3Y3%
EPS Next 5Y5.61%
Revenue Next Year-2.45%
Revenue Next 2Y-0.8%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.48, ICLR is valued correctly.
Based on the Price/Earnings ratio, ICLR is valued cheaply inside the industry as 96.55% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 25.45, ICLR is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 11.91, the valuation of ICLR can be described as reasonable.
98.28% of the companies in the same industry are more expensive than ICLR, based on the Price/Forward Earnings ratio.
ICLR is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.48 | ||
| Fwd PE | 11.91 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ICLR is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, ICLR is valued cheaply inside the industry as 96.55% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.27 | ||
| EV/EBITDA | 10.34 |
4.3 Compensation for Growth
The decent profitability rating of ICLR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.82
EPS Next 2Y-0.67%
EPS Next 3Y3%
5. Dividend
5.1 Amount
ICLR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
164.56
+6.44 (+4.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners102.62%
Inst Owner Change-0.43%
Ins Owners0.65%
Ins Owner ChangeN/A
Market Cap12.80B
Revenue(TTM)8.10B
Net Income(TTM)599.48M
Analysts76.67
Price Target209.8 (27.49%)
Short Float %2.44%
Short Ratio1.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.77%
Min EPS beat(2)-1.21%
Max EPS beat(2)-0.34%
EPS beat(4)1
Avg EPS beat(4)-0.63%
Min EPS beat(4)-1.21%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.34%
EPS beat(12)2
Avg EPS beat(12)-1.79%
EPS beat(16)5
Avg EPS beat(16)-1.4%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-2.61%
Max Revenue beat(4)1.03%
Revenue beat(8)1
Avg Revenue beat(8)-2.24%
Revenue beat(12)1
Avg Revenue beat(12)-2.14%
Revenue beat(16)1
Avg Revenue beat(16)-2.06%
PT rev (1m)-4.69%
PT rev (3m)-5.91%
EPS NQ rev (1m)-3.7%
EPS NQ rev (3m)-5.84%
EPS NY rev (1m)-1.01%
EPS NY rev (3m)-1.62%
Revenue NQ rev (1m)1.53%
Revenue NQ rev (3m)0.2%
Revenue NY rev (1m)1.2%
Revenue NY rev (3m)0.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.48 | ||
| Fwd PE | 11.91 | ||
| P/S | 1.58 | ||
| P/FCF | 13.27 | ||
| P/OCF | 11.22 | ||
| P/B | 1.37 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.34 |
EPS(TTM)13.19
EY8.02%
EPS(NY)13.81
Fwd EY8.39%
FCF(TTM)12.4
FCFY7.53%
OCF(TTM)14.66
OCFY8.91%
SpS104.19
BVpS120.03
TBVpS-38.28
PEG (NY)N/A
PEG (5Y)0.82
Graham Number188.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROCE | 8.53% | ||
| ROIC | 6.74% | ||
| ROICexc | 6.98% | ||
| ROICexgc | 176.34% | ||
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% | ||
| FCFM | 11.9% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexgc growth 3Y-4.45%
ROICexgc growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score6
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Debt/EBITDA | 1.89 | ||
| Cap/Depr | 45.31% | ||
| Cap/Sales | 2.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.92% | ||
| Profit Quality | 160.84% | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | 2 |
F-Score6
WACC8.46%
ROIC/WACC0.8
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
EPS Next Y-4.67%
EPS Next 2Y-0.67%
EPS Next 3Y3%
EPS Next 5Y5.61%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
Revenue Next Year-2.45%
Revenue Next 2Y-0.8%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
EBIT growth 1Y-0.88%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year0.82%
EBIT Next 3Y3.29%
EBIT Next 5Y4.34%
FCF growth 1Y86.71%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y72.39%
OCF growth 3Y15.78%
OCF growth 5Y25.55%
ICON PLC / ICLR FAQ
Can you provide the ChartMill fundamental rating for ICON PLC?
ChartMill assigns a fundamental rating of 5 / 10 to ICLR.
What is the valuation status of ICON PLC (ICLR) stock?
ChartMill assigns a valuation rating of 7 / 10 to ICON PLC (ICLR). This can be considered as Undervalued.
Can you provide the profitability details for ICON PLC?
ICON PLC (ICLR) has a profitability rating of 6 / 10.
How financially healthy is ICON PLC?
The financial health rating of ICON PLC (ICLR) is 5 / 10.
What is the earnings growth outlook for ICON PLC?
The Earnings per Share (EPS) of ICON PLC (ICLR) is expected to decline by -4.67% in the next year.